FindTrial
Sign In

INBRX-106

DRUG3 trials

Sponsors

Inhibrx Biosciences Inc., Inhibrx Biosciences, Inc, Providence Health & Services

Conditions

HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Triple Negative Breast Cancer

Phase 2

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
RecruitingNCT06295731
Inhibrx Biosciences, IncHead and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Start: 2024-05-14End: 2031-05-01Target: 450Updated: 2026-10-28
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
RecruitingNCT06353997
Providence Health & ServicesTriple Negative Breast Cancer
Start: 2024-09-05End: 2029-06-01Target: 12Updated: 2026-09-16
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)
RecruitingCTIS2024-515538-34-00
Inhibrx Biosciences Inc.Head and Neck Squamous Cell Carcinoma
Start: 2025-02-27Target: 175Updated: 2025-10-08

Related Papers

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058
The Journal of Immunology2025-11-01
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.
Journal of Clinical Oncology2025-05-28